BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8849571)

  • 1. Effect of follicle stimulating hormone or human chorionic gonadotrophin treatment on the production of gonadotrophin surge attenuating factor (GnSAF) during the luteal phase of the human menstrual cycle.
    Messinis IE; Lolis D; Zikopoulos K; Milingos S; Kollios G; Seferiadis K; Templeton AA
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):169-75. PubMed ID: 8849571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of varying concentrations of follicle stimulating hormone on the production of gonadotrophin surge attenuating factor (GnSAF) in women.
    Messinis IE; Lolis D; Papadopoulos L; Tsahalina T; Papanikolaou N; Seferiadis K; Templeton AA
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):45-50. PubMed ID: 8348707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of gonadotrophin surge-attenuating factor during the luteal phase in superovulated women.
    Messinis IE; MacTavish A; Templeton AA
    J Reprod Fertil; 1993 Jan; 97(1):271-5. PubMed ID: 8464020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone.
    Messinis IE; Milingos S; Zikopoulos K; Hasiotis G; Seferiadis K; Lolis D
    Hum Reprod; 1998 Sep; 13(9):2415-20. PubMed ID: 9806260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the action of gonadotrophin surge-attenuating factor by gonadotrophin-releasing hormone.
    Messinis IE; Lolis D; Zikopoulos K; Tsahalina E; Seferiadis K; Templeton AA
    Hum Reprod; 1994 Aug; 9(8):1437-41. PubMed ID: 7989501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in gonadotrophin response to gonadotrophin releasing hormone in normal women following bilateral ovariectomy.
    Alexandris E; Milingos S; Kollios G; Seferiadis K; Lolis D; Messinis IE
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):721-6. PubMed ID: 9497880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicle stimulating hormone stimulates the production of gonadotrophin surge attenuating factor (GnSAF) in vivo.
    Messinis IE; Hirsch P; Templeton AA
    Clin Endocrinol (Oxf); 1991 Nov; 35(5):403-7. PubMed ID: 1814653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuating activity of the ovary on LH response to GnRH during the follicular phase of the cycle.
    Dimitraki M; Messini CI; Dafopoulos K; Gioka T; Koutlaki N; Garas A; Georgoulias P; Messinis IE
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):439-43. PubMed ID: 23909480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in pituitary sensitivity to GnRH in estrogen-treated post-menopausal women: evidence that gonadotrophin surge attenuating factor plays a physiological role.
    Dafopoulos K; Kotsovassilis CG; Milingos S; Kallitsaris A; Galazios G; Zintzaras E; Sotiros P; Messinis IE
    Hum Reprod; 2004 Sep; 19(9):1985-92. PubMed ID: 15229199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an increase in FSH on the production of gonadotrophin-surge-attenuating factor in women.
    Messinis IE; Lolis D; Zikopoulos K; Tsahalina E; Seferiadis K; Templeton AA
    J Reprod Fertil; 1994 Aug; 101(3):689-95. PubMed ID: 7966027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aspects of the endocrinology of the menstrual cycle.
    Messinis IE; Messini CI; Dafopoulos K
    Reprod Biomed Online; 2014 Jun; 28(6):714-22. PubMed ID: 24745832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary gonadotrophin secretion during the first weeks of pregnancy.
    Jeppsson S; Rannevik G; Thorell JI
    Acta Endocrinol (Copenh); 1977 May; 85(1):177-88. PubMed ID: 324219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher gonadotrophin surge-attenuating factor bioactivity is found in small follicles from superovulated women.
    Fowler PA; Fraser M; Cunningham P; Knight PG; Byrne B; McLaughlin EA; Wardle PG; Hull MG; Templeton A
    J Endocrinol; 1994 Oct; 143(1):33-44. PubMed ID: 7964320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
    Grimes EM; Thompson IE; Taymor ML
    Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women with poor response to IVF have lowered circulating gonadotrophin surge-attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles.
    Martinez F; Barri PN; Coroleu B; Tur R; Sorsa-Leslie T; Harris WJ; Groome NP; Knight PG; Fowler PA
    Hum Reprod; 2002 Mar; 17(3):634-40. PubMed ID: 11870115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.